These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14552866)

  • 1. Primate models of Parkinson's disease.
    Collier TJ; Steece-Collier K; Kordower JH
    Exp Neurol; 2003 Oct; 183(2):258-62. PubMed ID: 14552866
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.
    Diguet E; Gross CE; Bezard E; Tison F; Stefanova N; Wenning GK
    Neurology; 2004 Jan; 62(1):158; author reply 158-9. PubMed ID: 14718729
    [No Abstract]   [Full Text] [Related]  

  • 3. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
    Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
    Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Doo AR; Kim ST; Kim SN; Moon W; Yin CS; Chae Y; Park HK; Lee H; Park HJ
    Neurol Res; 2010 Feb; 32 Suppl 1():88-91. PubMed ID: 20034453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
    Walsh S; Finn DP; Dowd E
    Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Modeling Parkinson's disease and objectifying the nigro-striatum system dysfunction].
    Chekhonin VP; Baklaushev VP; Dmitrieva TB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(1):59-68. PubMed ID: 14870697
    [No Abstract]   [Full Text] [Related]  

  • 9. Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates.
    McCallum SE; Parameswaran N; Perez XA; Bao S; McIntosh JM; Grady SR; Quik M
    J Neurochem; 2006 Feb; 96(4):960-72. PubMed ID: 16412097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning.
    Goldberg NR; Hampton T; McCue S; Kale A; Meshul CK
    J Neurosci Res; 2011 Oct; 89(10):1698-706. PubMed ID: 21748776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
    Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
    Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
    Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
    J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T.
    Heo H; Ahn JB; Lee HH; Kwon E; Yun JW; Kim H; Kang BC
    NMR Biomed; 2017 Feb; 30(2):. PubMed ID: 28028868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
    Ando K; Maeda J; Inaji M; Okauchi T; Obayashi S; Higuchi M; Suhara T; Tanioka Y
    Psychopharmacology (Berl); 2008 Jan; 195(4):509-16. PubMed ID: 17879087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GABA: Inhibition brings new excitement in Parkinson's disease.
    Castela I
    Mov Disord; 2016 Mar; 31(3):297. PubMed ID: 26861776
    [No Abstract]   [Full Text] [Related]  

  • 17. Animal models of Parkinson's disease.
    Betarbet R; Sherer TB; Greenamyre JT
    Bioessays; 2002 Apr; 24(4):308-18. PubMed ID: 11948617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
    Liu LX; Chen WF; Xie JX; Wong MS
    Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Benner EJ; Mosley RL; Destache CJ; Lewis TB; Jackson-Lewis V; Gorantla S; Nemachek C; Green SR; Przedborski S; Gendelman HE
    Proc Natl Acad Sci U S A; 2004 Jun; 101(25):9435-40. PubMed ID: 15197276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations.
    Ando K; Inoue T; Hikishima K; Komaki Y; Kawai K; Inoue R; Nishime C; Nishinaka E; Urano K; Okano H
    Behav Pharmacol; 2020 Feb; 31(1):45-60. PubMed ID: 31625972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.